New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn

Zachary Brennan

Senior Editor

As Capitol Hill begins to wake up to the financial and scientific mess behind the FDA’s approval of Biogen’s new controversial Alzheimer’s drug Aduhelm, nonprofit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

New Alzheimer's drug ap­proval fall­out: Pub­lic Cit­i­zen seeks re­moval of FDA's Wood­cock, Cavaz­zoni and Dunn

Senior Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn